Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer-Reference-Cited by-同舟云学术

Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer

Published:2020-03 Issue:1 Volume:19 Page:32-38.e3
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Le Dung T.,Ott Patrick A.,Korytowsky Beata,Le Hannah,Le T. Kim,Zhang Ying,Maglinte Gregory A.,Abraham Pranav,Patel Dhiren,Shangguan Tong,Chau Ian

Funder

Bristol-Myers Squibb

Merck Serono

Amgen

ARMO Biosciences

Array

AstraZeneca

Celldex

CytomX

Genentech

Neon Therapeutics

Novartis

Pfizer

Eli Lilly

Janssen-Cilag

Sanofi

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference19 articles.

1. Cancer statistics, 2018;Siegel;CA Cancer J Clin,2018

2. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC--a randomized phase III trial;Hecht;J Clin Oncol,2016

3. Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) Study

4. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study);Shen;Gastric Cancer,2015

5. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial;Waddell;Lancet Oncol,2013

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Personalized Oncology;Cancers;2024-08-16

2. Fourth-line Trastuzumab deruxtecan in HER2-positive metastatic gastric cancer;Meditsinskiy sovet = Medical Council;2024-07-25

3. Outcomes in older adults with metastatic esophageal and gastric carcinoma treated with palliative chemotherapy;The Oncologist;2024-07-24

4. Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer;World Journal of Gastrointestinal Oncology;2024-06-15

5. Efficacy of immunotherapy in advanced gastric cancer: preliminary results of a multicenter observational study;Malignant tumours;2024-05-24